Table 1.
Baseline characteristics stratified by AFP cutoffs.
| ≥75% decrease in AFP | ≤10% increase in AFP | ||||
|---|---|---|---|---|---|
| Yes | No | Yes | No | All patients included in analysis | |
| (n = 39) | (n = 111) | (n = 107) | (n = 43) | (N = 150) | |
| Median age (IQR), years | 61.0 (53.0–70.5) | 63.0 (54.5–69.0) | 61.0 (53.0–68.5) | 65.0 (60.5–72.5) | 62.0 (54.0–70.0) |
| Sex, n (%) | |||||
| Female | 5 (12.8) | 23 (20.7) | 16 (15.0) | 12 (27.9) | 28 (18.7) |
| Male | 34 (87.2) | 88 (79.3) | 91 (85.0) | 31 (72.1) | 122 (81.3) |
| Race, n (%) | |||||
| Asian | 23 (59.0) | 71 (64.0) | 64 (59.8) | 30 (69.8) | 94 (62.7) |
| White | 14 (35.9) | 28 (25.2) | 33 (30.8) | 9 (20.9) | 42 (28.0) |
| Other | 0 (0.0) | 4 (3.6) | 4 (3.7) | 0 | 4 (2.7) |
| Unknown | 2 (5.1) | 8 (7.2) | 6 (5.6) | 4 (9.3) | 10 (6.7) |
| Median baseline AFP (IQR), ng/mL | 2,907.1 (505.0–14,821.1) | 615.7 (75.3–7,441.0) | 1,485.8 (162.6–8,605.2) | 1,193.0 (75.3–9,112.0) | 1,354.5 (121.0–8,735.7) |
| ECOG PS, n (%) | |||||
| 0 | 26 (66.7) | 75 (67.6) | 72 (67.3) | 29 (67.4) | 101 (67.3) |
| 1 | 13 (33.3) | 36 (32.4) | 35 (32.7) | 14 (32.6) | 49 (32.7) |
| Child–Pugh class, n (%) | |||||
| A5 | 31 (79.5) | 75 (67.6) | 76 (71.0) | 30 (69.8) | 106 (70.7) |
| A6 | 8 (20.5) | 36 (32.4) | 31 (29.0) | 13 (30.2) | 44 (29.3) |
| Etiology, n (%) | |||||
| HBV | 18 (46.2) | 63 (56.8) | 58 (54.2) | 23 (53.5) | 81 (54.0) |
| HCV | 14 (35.9) | 20 (18.0) | 27 (25.2) | 7 (16.3) | 34 (22.7) |
| Nonviral | 7 (17.9) | 28 (25.2) | 22 (20.6) | 13 (30.2) | 35 (23.3) |
| BCLC stage, n (%) | |||||
| A1/A4 | 0 (0.0) | 5 (4.5) | 4 (3.7) | 1 (2.3) | 5 (3.3) |
| B | 3 (7.7) | 14 (12.6) | 10 (9.3) | 7 (16.3) | 17 (11.3) |
| C | 36 (92.3) | 92 (82.9) | 93 (86.9) | 35 (81.4) | 128 (85.3) |
| Extrahepatic spread, n (%) | 28 (71.8) | 73 (65.8) | 72 (67.3) | 29 (67.4) | 101 (67.3) |
| Median time from initial diagnosis (IQR), months | 4.7 (1.7–9.4) | 6.3 (2.1–18.2) | 4.7 (1.8–11.6) | 9.2 (2.1–25.2) | 6.0 (1.9–15.4) |
| Prior locoregional therapy,an (%) | 22 (56.4) | 73 (65.8) | 63 (58.9) | 32 (74.4) | 95 (63.3) |
| Median number of metastatic sites (IQR), n | 0.0 (0.0–1.0) | 1.0 (0.0–1.0) | 1.0 (0.0–1.0) | 1.0 (0.0–1.0) | 1.0 (0.0–1.0) |
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance score; IQR, interquartile range.
aIncludes local therapy, radiotherapy, and surgery.